S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
S&P 500   3,110.29 (+0.22%)
DOW   27,875.62 (+0.39%)
QQQ   201.83 (+0.06%)
CGC   18.41 (-9.27%)
BABA   186.78 (+1.04%)
GE   11.55 (+0.17%)
T   37.75 (+0.40%)
ACB   2.70 (-13.46%)
F   8.89 (+2.07%)
BAC   33.18 (+1.04%)
DIS   148.29 (+0.95%)
Log in

Aurinia Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:AUPH)

$6.12
-0.11 (-1.77 %)
(As of 11/22/2019 04:00 PM ET)
Today's Range
$6.08
Now: $6.12
$6.30
50-Day Range
$3.91
MA: $5.00
$6.18
52-Week Range
$3.52
Now: $6.12
$7.85
Volume59,604 shs
Average Volume1.13 million shs
Market Capitalization$577.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUPH
CUSIPN/A
Phone250-744-2487

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$1.31 per share

Profitability

Net Income$-64,120,000.00
Net Margins-19,483.96%

Miscellaneous

Employees39
Market Cap$577.05 million
Next Earnings Date3/17/2020 (Estimated)
OptionableOptionable

Receive AUPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.


Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.02. The biotechnology company earned $0.23 million during the quarter, compared to analyst estimates of $0.05 million. Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.79%. View Aurinia Pharmaceuticals' Earnings History.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Aurinia Pharmaceuticals.

What price target have analysts set for AUPH?

7 Wall Street analysts have issued twelve-month price objectives for Aurinia Pharmaceuticals' shares. Their forecasts range from $11.00 to $25.00. On average, they expect Aurinia Pharmaceuticals' stock price to reach $16.50 in the next year. This suggests a possible upside of 169.6% from the stock's current price. View Analyst Price Targets for Aurinia Pharmaceuticals.

What is the consensus analysts' recommendation for Aurinia Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aurinia Pharmaceuticals.

What are Wall Street analysts saying about Aurinia Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (11/19/2019)
  • 2. HC Wainwright analysts commented, "Buy ILJIN seeks effective control of Aurinia, or at least substantial influence, wholly disproportionate to its current holdings. Over the weekend, Aurinia’s largest shareholder (about 14% S/O), ILJIN SNT Co., Ltd. (private; Seoul, South Korea) launched a proxy contest to elect at least 3 directors to the upcoming Annual General Meeting (AGM) to be held on Wednesday, June 26, 2019. ILJIN is a life science-focused investment fund with a portfolio of positions in about 12 companies (according to its website), including Aurinia which appears to be its largest and longest holding, with a total of about $58M invested since 2010, according to ILJIN." (6/4/2019)

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

Headlines about AUPH stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Aurinia Pharmaceuticals.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a increase in short interest in October. As of October 31st, there was short interest totalling 9,100,000 shares, an increase of 11.5% from the September 30th total of 8,160,000 shares. Based on an average daily trading volume, of 960,900 shares, the days-to-cover ratio is currently 9.5 days. Approximately 13.6% of the shares of the company are short sold. View Aurinia Pharmaceuticals' Current Options Chain.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Richard M. Glickman, Advisor (Age 61)
  • Dr. Neil Solomons M.D., Chief Medical Officer

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include SG Americas Securities LLC (0.05%), Patriot Financial Group Insurance Agency LLC (0.02%), Benjamin F. Edwards & Company Inc. (0.01%) and Tower Research Capital LLC TRC (0.01%).

Which institutional investors are buying Aurinia Pharmaceuticals stock?

AUPH stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Tower Research Capital LLC TRC , Patriot Financial Group Insurance Agency LLC and Benjamin F. Edwards & Company Inc..

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $6.12.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of $577.05 million and generates $460,000.00 in revenue each year. The biotechnology company earns $-64,120,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe.View Additional Information About Aurinia Pharmaceuticals.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is http://www.auriniapharma.com/.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 MARKHAM STREET, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-744-2487 or via email at [email protected]


MarketBeat Community Rating for Aurinia Pharmaceuticals (NASDAQ AUPH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  442 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  721
MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Featured Article: What is the QQQ ETF?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel